Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Over the course of 12 weeks, participants taking the highest dose of amycretin (2 x 50 mg) lost an average of 13.1% of their body weight. Those on a smaller dose (50 mg) lost about 10.4%. In ...

Furthermore, Novo Nordisk is currently in the early stages ... Finally, the regulatory process for Amycretin is ongoing, with an FDA decision expected in the coming months. The company anticipates ...

Novo Nordisk's oral GLP-1 drug Rybelsus ... The company is also studying weight-loss pill amycretin, which targets the same gut hormone that Wegovy mimics, known as GLP-1, but also a pancreas ...

Novo Nordisk announced launching a direct-to-patient ... A recent trial of its next-generation obesity treatment, amycretin, showed positive results, temporarily lifting its share price in January.

Novo Nordisk A/S (NYSE:NVO ... Besides, last month the Amycretin trial results were released and stock showed an upward hike due to the satisfying results. Even though the drug won’t be ...